3 completed, 3 recruiting, 3 unknown, 2 active not recruiting. 5 Phase 2, 2 Not applicable, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Suspended 1, Terminated 1 |
| Not applicable | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Advanced Prostate Carcinoma: new trials by email Literature Review of Advanced Prostate Carcinoma trials Research Report on Advanced Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review - Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 210 | 2024-07-09 | 2026-10-07 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-09-21 | 2026-11-06 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Physical Function During ARSI Treatment androgen receptor signaling inhibitors - Advanced Prostate Carcinoma | Completed | UNC Lineberger Comprehensive Cancer Center | 24 | 2022-10-13 | 2025-01-09 | |
| Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer Participant Surveys, Mobile app - Prostate Cancer, Advanced Prostate Carcinoma | Not applicable | Recruiting | University of California, San Francisco | 250 | 2022-05-12 | 2026-03-09 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Improving Diagnosis and Treatment of Metastatic Advanced Prostate Cancer Post-treatment CT-guided bone marrow biopsy - Advanced Prostate Carcinoma | Unknown | Royal Marsden NHS Foundation Trust | 50 | 2021-07-30 | 2021-07-30 | |
| Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA Darolutamide, Radiotherapy - Advanced Prostate Carcinoma, Cancer of Prostate | Phase 2 | Active not recruiting | Trans Tasman Radiation Oncology Group | 65 | 2021-06-02 | 2025-08-21 |
| The Wolverhampton Assessment Tool, a Tool for Patient-reported Wellbeing in the Context of Prostate Cancer Wolverhampton Assessment Tool - Advanced Prostate Carcinoma | Not applicable | Unknown | University of Wolverhampton | 50 | 2020-09-01 | 2021-10-05 |
| Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer Hyperpolarized C13, Magnetic Resonance Imaging (MRI) - Prostate Cancer, Advanced Prostate Carcinoma | Phase 2 | Suspended | Ivan de Kouchkovsky, MD | 75 | 2020-07-16 | 2026-06-23 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 23 | 2018-09-24 | 2026-04-29 |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) Prostate Cancer Metastatic, Castration Resistant Prostatic Cancer | Unknown | Universität des Saarlandes | 500 | 2016-01-01 | 2022-12-08 | |
| An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation Eligard 45 mg Exposure - Advanced Prostate Carcinoma | Completed | Astellas Pharma Europe B.V. | 645 | 2013-09-01 | 2016-08-16 |
Prostatic Neoplasms (9) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Breast Neoplasms (2) · Pancreatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · HIV Infections (1) · Lung Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1)
Neoplasms (12) · Genital Diseases (10) · Genital Diseases, Male (10) · Genital Neoplasms, Male (10) · Male Urogenital Diseases (10) · Neoplasms by Site (10) · Prostatic Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Adnexal Diseases (3) · Breast Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3)
Biopsy (2) · Letrozole (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · darolutamide (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · AZD8186 (1) · Ado-Trastuzumab Emtansine (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · Anastrozole (1) · Bevacizumab (1) · Capecitabine (1) · Carboplatin (1)
National Cancer Institute (NCI) (2) · OHSU Knight Cancer Institute (2) · Astellas Pharma Europe B.V. (1) · City of Hope Medical Center (1) · Ivan de Kouchkovsky, MD (1) · Mayo Clinic (1) · Royal Marsden NHS Foundation Trust (1) · Trans Tasman Radiation Oncology Group (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, San Francisco (1) · University of Wolverhampton (1) · Universität des Saarlandes (1)
United States (8) · United Kingdom (2) · Australia (1) · Germany (1) · Russia (1) · Singapore (1)
Alison M Schram (1) · Arun Azad (1) · Charles D Lopez, MD, PhD (1) · Daniel Kwon, MD (1) · David Matheson, PhD (1) · Erik D Hanson, PhD (1) · Haiying Cheng (1) · Ivan de Kouchkovsky, MD (1) · Lara Davis (1) · Nina Tunariu (1) · Roxana S. Dronca, MD (1) · Samer Ezziddin, MSc, MD, PhD (1) · Shankar Siva (1) · William Dale (1)
PMID 36351402, PMID 37889298, PMID 38769643, PMID 39008067, PMID 40619537, PMID 40939237, PMID 42847673
P30CA033572 (1), R01CA215694 (1), U01EB026412 (1), UM1CA186691 (1)